Orion is developing the Finnish life science industry in a unique collaboration project
03 Junio 2024 - 1:30AM
Orion is developing the Finnish life science industry in a unique
collaboration project
ORION CORPORATION PRESS RELEASE 03 June 2024 at 09.30 EEST
Orion is
developing the Finnish life science industry in a unique
collaboration project
Orion is participating in a project led by the University of
Turku for which Business Finland recently granted 11.7M€ funding.
The project seeks to enhance advanced pharmaceutical and life
science manufacturing in Finland. The LifeFactFuture project
combines world-class-excellence of Finnish life science companies,
technology companies, and academic researchers. In addition to the
collaboration, Orion has its own parallel project that aims to
utilize new technologies in the pharmaceutical industry. The
funding decision for this collaboration demonstrates how public
funding for research and development can enable important
university-industry research cooperation. The funding decision is
among the largest received at the University of Turku in the
history of Business Finland.
The LifeFactFuture consortium includes the University of Turku,
the University of Helsinki, some of Finland's leading life science
manufacturers, and data and technology companies. In addition, the
Finnish Medicines Agency, Fimea, is involved in the project to
ensure compliance between technological development and
pharmaceutical legislation. The goal of the project collaboration
is to speed up the introduction of digital solutions and more
efficient utilization of data and to make Finland the most
attractive place in the world for investments in life science
manufacturing.
In the project's funding decision, Business Finland states that
the unique consortium expertise can make Finland a strategic and
profitable manufacturing country and improve its position as a hub
for global business ecosystems. The project strengthens the
competitive advantage and ability of the companies in the field in
international markets and aims to increase turnover for both the
life science and technology industries.
The project creates an opportunity for collaboration
between committed experts
Three major players in the life science industry, Bayer, Orion,
and Revvity, have their own projects within the consortium. In
addition, the LifeFactFuture consortium includes the technology
sector with Brightly Works, Bittium, Darekon, Nokia, and Vaisala
involved in the consortium and a wide range of other
subcontractors. The project is linked to Bittium's Seamless and
Secure Connectivity Business Finland Veturi project and its theme
of significant development of operational models that promote the
agile development of medical software (RegOps).
In addition to the collaboration project, Orion has its own
parallel project aiming to leverage new technologies and the
opportunities offered by digitalization and data analytics,
especially in enhancing data processing. The project's goal is to
better understand and control production processes and develop them
by utilizing information technology, automation, new technologies,
and effective data use. Orion's project's total funding is €1
million, of which €600.000 comes from Orion.
The project consists of three key areas:
- Roadmap for Data Utilization
- Imaging Combined with AI Solutions
- Monitoring and Process Control
Juhani Kankaanpää, Orion’s Senior Vice
President for Global Operations, describes that the project
significantly supports the development of new capabilities and
expertise at Orion.
“The LifeFactFuture project focuses on the ways that
pharmaceutical manufacturing can be advanced by utilizing new
technologies. This project is a great opportunity for Orion to
actively participate in understanding and improving the
capabilities of new technologies, and therefore also continuously
enhancing competitiveness”, says Kankaanpää.
The collaboration project enables the creation of new networks
and provides an opportunity to engage in valuable cooperation with
new academic contacts. In addition, Orion supports Finnish business
activities by procuring services from Finnish small and
medium-sized enterprises and higher education institutions. This
collaboration builds shared expertise and creates a broader
understanding of the future requirements of the pharmaceutical
industry.
Contact
person:Terhi Ormio, Vice President, Communications
tel. +358 50 966 4646
terhi.ormio@orion.fi
Publisher:Orion
CorporationCommunicationsOrionintie 1A, FI-02200 Espoo,
Finlandhttp://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a
builder of well-being. We develop, manufacture and market human and
veterinary pharmaceuticals and active pharmaceutical ingredients.
Orion has an extensive portfolio of proprietary and generic
medicines and consumer health products. The core therapy areas of
our pharmaceutical R&D are oncology and pain. Proprietary
products developed by Orion are used to treat cancer, neurological
diseases and respiratory diseases, among others. Orion's net sales
in 2023 amounted to EUR 1,190 million and the company had about
3,600 employees at the end of the year. Orion's A and B shares are
listed on Nasdaq Helsinki.
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024